It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Intestinal microbiota (IM) diversity and composition regulates host immunity and affects outcomes after allogeneic stem cell transplantation (allo-HSCT). We evaluated if the oral mucosa microbiota (OM) could impact the outcomes in patients who underwent allo-HSCT. Samples from the oral mucosa of 30 patients were collected at three time points: before the conditioning regimen, at aplasia, and at engraftment. We analyzed the associations of OM diversity and composition with allo-HSCT outcomes. Lower OM diversity at preconditioning was associated with a higher risk of relapse at 3 years (68% versus 33%, respectively; P = 0.04). Dominance (relative abundance ≥ 30%) by a single genus at preconditioning was also associated with a higher risk of relapse (63% versus 36% at 3 years, respectively; P = 0.04), as well as worse progression-free survival (PFS; 19% versus 55%, respectively; P = 0.01), and overall survival (OS) at 3 years (38% versus 81%, respectively; P = 0.02). In our study we observed that OM dysbiosis is associated with a higher risk of relapse and worse survival after allo-HSCT.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hospital Sírio Libanês, Centro de Oncologia, São Paulo, Brazil (GRID:grid.413471.4) (ISNI:0000 0000 9080 8521); Universidade Federal de São Paulo, São Paulo, Brazil (GRID:grid.411249.b) (ISNI:0000 0001 0514 7202)
2 Hospital Sírio Libanês, Centro de Oncologia Molecular, São Paulo, Brazil (GRID:grid.413471.4) (ISNI:0000 0000 9080 8521); Universidade de São Paulo, Departamento de Bioquímica, Instituto de Química, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
3 Hospital Sírio Libanês, Centro de Oncologia Molecular, São Paulo, Brazil (GRID:grid.413471.4) (ISNI:0000 0000 9080 8521)
4 Hospital Sírio Libanês, Centro de Oncologia, São Paulo, Brazil (GRID:grid.413471.4) (ISNI:0000 0000 9080 8521)
5 Hospital Sírio Libanês, Centro de Oncologia, São Paulo, Brazil (GRID:grid.413471.4) (ISNI:0000 0000 9080 8521); Universidade de São Paulo/ICESP, Hospital das Clínicas da Faculdade de Medicina, Sao Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); NHS-BT, Churchill Hospital, Oxford, UK (GRID:grid.436365.1) (ISNI:0000 0000 8685 6563)